Enhancement of Osteogenic Induction by LL37 Modified with a Collagen-Binding Domain In Vitro and In Vivo

被引：0

作者：

Lin, Xiaoxuan ^{[1
]}

Chen, Sipeng ^{[1
]}

Quan, Jingjing ^{[1
]}

Zhang, Qi ^{[1
]}

Liao, Muzi ^{[1
]}

Ma, Xinyue ^{[1
]}

Zheng, Yuyan ^{[2
]}

Mai, Sui ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Guanghua Sch Stomatol, Hosp Stomatol, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China

[2] Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Dept Stomatol,Shenzhen Peoples Hosp,Sch Clin Med, Shenzhen, Peoples R China

来源：

INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS | 2021年 / 27卷 / 03期

基金：

中国国家自然科学基金;

关键词：

LL37; Collagen-binding domain; Osteoinduction;

D O I：

10.1007/s10989-021-10216-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bone defect diseases, particularly those induced by inflammation, pose a challenge for the design of ideal drug-loading scaffolds that could facilitate bone repair and eliminate inflammatory pathogens. Antimicrobial peptides LL37 is considered a promising alternative loading drug due to its broad-spectrum antimicrobial effect and various bio-functions, including osteogenic induction. In this study, we synthesized modified LL37 by adding a collagen-binding domain (CBD) to achieve specific binding to collagen and a slow release pattern. The modified peptide was indicated to exhibit similar biological activities as natural LL37 on rat BMSCs, including promotion of migration activity, anti-inflammatory activity and osteogenic induction in vitro. Ectopic bone formation experiments further confirmed the angiogenesis and osteoinduction activities in vivo. Collectively, the results indicate that LL37-CBD may be a potential loading drug for preventative and curative applications in the treatment of inflammation-induced bone diseases.

引用

页码：1861 / 1873

页数：13